Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …

With the continuation of the pandemic, many severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variants have appeared around the world. Owing to a possible risk of …

Summary Background The SARS-CoV-2 delta (B. 1.617. 2) variant was first detected in
England in March, 2021. It has since rapidly become the predominant lineage, owing to high …

Background: Between February and June 2021, the initial wild-type strains of SARS-CoV-2
were supplanted in Ontario, Canada, by new variants of concern (VOCs), first those with the …

The emergence and rapid spread of SARS-CoV-2 variants may affect vaccine efficacy
substantially. The Omicron variant termed BA. 2, which differs substantially from BA. 1 based …

During the COVID-19 pandemic, SARS-CoV-2 variants have emerged and spread
worldwide. The Delta (B. 1.617. 2) variant was first reported in India in October 2020 and …

CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in
several countries. However, its immunogenicity in immunocompromised individuals has not …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

Background Remdesivir is an antiviral medicine approved for the treatment of mild‐to‐
moderate coronavirus disease 2019 (COVID‐19). This led to widespread implementation …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
coronavirus responsible for the global COVID-19 pandemic. Herein, we provide evidence …